David Epstein Sells 370 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David Epstein sold 370 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $43.40, for a total transaction of $16,058.00. Following the sale, the director directly owned 31,094 shares in the company, valued at $1,349,479.60. This trade represents a 1.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Trading Down 0.7%

TEM traded down $0.35 during mid-day trading on Wednesday, reaching $46.70. The stock had a trading volume of 3,491,891 shares, compared to its average volume of 5,862,125. The stock has a market capitalization of $8.39 billion, a P/E ratio of -32.43 and a beta of 3.58. Tempus AI, Inc. has a 52 week low of $40.77 and a 52 week high of $104.32. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30. The firm’s fifty day simple moving average is $51.41 and its two-hundred day simple moving average is $52.28.

Tempus AI (NASDAQ:TEM) last released its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. During the same period in the prior year, the company posted ($0.22) EPS. The company’s revenue was up 21.6% compared to the same quarter last year. On average, equities analysts predict that Tempus AI, Inc. will post -1.35 EPS for the current year.

Institutional Trading of Tempus AI

A number of hedge funds and other institutional investors have recently modified their holdings of TEM. Vanguard Group Inc. grew its stake in shares of Tempus AI by 8.7% in the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock valued at $605,772,000 after buying an additional 817,014 shares in the last quarter. ARK Investment Management LLC lifted its stake in Tempus AI by 5.3% in the fourth quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock valued at $446,275,000 after acquiring an additional 381,816 shares during the last quarter. GC Wealth Management RIA LLC acquired a new stake in Tempus AI in the fourth quarter valued at $399,267,000. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Tempus AI by 23.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after purchasing an additional 821,490 shares during the period. Finally, Amova Asset Management Americas Inc. lifted its stake in Tempus AI by 23.4% in the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after purchasing an additional 821,490 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on TEM. BTIG Research cut their target price on shares of Tempus AI from $80.00 to $70.00 and set a “buy” rating on the stock in a report on Monday. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a research report on Friday, July 31st. Wolfe Research assumed coverage on Tempus AI in a research note on Tuesday, June 2nd. They set a “peer perform” rating for the company. Lake Street Capital lowered shares of Tempus AI to a “hold” rating in a research note on Monday, July 20th. Finally, Jefferies Financial Group began coverage on shares of Tempus AI in a research report on Monday, April 13th. They set an “underperform” rating and a $35.00 price objective for the company. Nine research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Tempus AI has an average rating of “Hold” and an average price target of $64.92.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.